Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biological therapy in Crohn's disease.

J N Gordon1, T T MacDonald

  • 1Division of Infection, Inflammation, and Repair, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD.

Hospital Medicine (London, England : 1998)
|January 2, 2004
PubMed
Summary

Tumour necrosis factor-alpha (TNF-α) is central to Crohn's disease treatment. New biological therapies targeting immune pathways offer future treatment advancements for refractory cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

T-bet controls intestinal mucosa immune responses via repression of type 2 innate lymphoid cell function.

Mucosal immunology·2018
Same author

Recent advances in gut immunology.

Parasite immunology·2017
Same author

Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease.

Mucosal immunology·2016
Same author

Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth.

Oncogene·2014
Same author

Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut.

Mucosal immunology·2014
Same author

A functional role for Smad7 in sustaining colon cancer cell growth and survival.

Cell death & disease·2014

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Crohn's disease is an inflammatory bowel disease with complex immunopathology.
  • Tumour necrosis factor-alpha (TNF-α) has been identified as a key mediator in Crohn's disease pathogenesis.

Purpose of the Study:

  • To highlight the impact of TNF-α targeted therapy on Crohn's disease.
  • To discuss the future development of novel biological therapies for Crohn's disease.

Main Methods:

  • Review of clinical practice and therapeutic advancements.
  • Analysis of immunopathological research in Crohn's disease.

Main Results:

  • Infliximab, a TNF-α inhibitor, has revolutionized the treatment of refractory Crohn's disease.
  • Understanding immune pathways is driving the development of new biological agents.

Conclusions:

  • TNF-α blockade represents a significant therapeutic advance in Crohn's disease management.
  • Future research in immunopathology will likely yield more targeted and effective biological therapies for Crohn's disease.

Related Experiment Videos